A depressive episode is a mood disorder episode characterized in ICD coding as a single episode of major depressive symptoms. It includes clinical presentations ranging from mild to severe and may include psychotic features in severe forms. It is distinct from recurrent depressive disorder.
The bipolar depression treatment pipeline includes over 10 therapies from 8+ companies, with recent Phase 3 trials initiated for azetukalner and multiple emerging drugs targeting novel pathways expected to launch by 2036.
COMPASS Pathways announced positive Phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant improvements across two pivotal trials with durability signals through 26 weeks and a generally well-tolerated safety profile.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07263321 |
Improving Treatment for Depression in General Practice Using a Step-by-Step Care Plan. |
RECRUITING | NA |
| NCT06426134 |
Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS |
COMPLETED | NA |
| NCT06355180 |
Esketamine vs ECT for Acute Suicidality |
COMPLETED | NA |
| NCT06152705 |
Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression |
RECRUITING | NA |
| NCT05910775 |
Role Of Non-Specific Effects in The Treatment of Depression With Esketamine |
TERMINATED | NA |
| NCT05708222 |
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) |
COMPLETED | |
| NCT05701345 |
Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder |
COMPLETED | NA |
| NCT05691647 |
Chronotherapy for Depressive Episodes |
RECRUITING | NA |
| NCT05686408 |
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) |
COMPLETED | PHASE2 |
| NCT05683028 |
RCT for Electroconvulsive Treatment Followed by Cognitive Control Training |
COMPLETED | NA |
